FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Facilitating Follow-Up Adherence for Abnormal Pap Smears

Not Applicable

Completed

Conditions: Uterine Cervical Neoplasms

Interventions: Behavioral: Cognitive-affective barriers counseling
Behavioral: Cognitive-affective barriers counseling via brochure
Behavioral: standard care

First Posted Date: 2012-03-23

Last Posted Date: 2012-03-23

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 211

Registration Number: NCT01561326

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Phase 2

Withdrawn

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma
Stage I Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2012-02-27

Last Posted Date: 2016-03-03

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT01539174

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer Recurrent
Non-small Cell Lung Cancer Metastatic

Interventions: Drug: MLN8237 and Erlotinib

First Posted Date: 2011-11-16

Last Posted Date: 2018-05-17

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 22

Registration Number: NCT01471964

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Procedure: quality-of-life assessment
Radiation: intensity-modulated radiation therapy
Radiation: 3-dimensional conformal radiation therapy

First Posted Date: 2011-11-11

Last Posted Date: 2020-05-08

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 24

Registration Number: NCT01470365

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Phase 2

Completed

Conditions: Recurrent Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma
Adult Angiosarcoma
Stage III Adult Soft Tissue Sarcoma

Interventions: Drug: pazopanib hydrochloride
Other: laboratory biomarker analysis
Procedure: positron emission tomography
Procedure: computed tomography
Radiation: fludeoxyglucose F 18

First Posted Date: 2011-10-31

Last Posted Date: 2022-08-19

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 29

Registration Number: NCT01462630

Locations: 🇺🇸
Hollings Cancer Center Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting

Not Applicable

Completed

Conditions: Prostate Cancer
Breast Cancer
Colorectal Cancer
Thoracic Cancer

Interventions: Other: CIS (Cancer Information Service) Information Sheet
Other: Facing Forward booklet

First Posted Date: 2011-09-27

Last Posted Date: 2011-10-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 340

Registration Number: NCT01440855

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Phase 1

Withdrawn

Conditions: Recurrent Salivary Gland Cancer
Recurrent Verrucous Carcinoma of the Oral Cavity
Salivary Gland Squamous Cell Carcinoma
Tongue Cancer
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Verrucous Carcinoma of the Larynx
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity

Interventions: Drug: everolimus
Drug: erlotinib hydrochloride
Procedure: biopsy
Other: laboratory biomarker analysis
Other: immunohistochemistry staining method
Genetic: polyacrylamide gel electrophoresis
Other: pharmacological study
Radiation: external beam radiation therapy
Genetic: microarray analysis

First Posted Date: 2011-04-11

Last Posted Date: 2023-04-04

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT01332279

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Phase 2

Completed

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Salivary Gland Cancer
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Verrucous Carcinoma of the Larynx

Interventions: Biological: cetuximab
Drug: paclitaxel
Drug: carboplatin
Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2011-03-16

Last Posted Date: 2018-02-26

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 24

Registration Number: NCT01316757

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Univesity of Rochester Medical Center, Rochester, New York, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

Phase 1

Terminated

Conditions: Recurrent Colon Cancer
Mucinous Adenocarcinoma of the Rectum
Signet Ring Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Rectum
Stage IV Colon Cancer
Stage IV Rectal Cancer
Liver Metastases
Recurrent Rectal Cancer

Interventions: Combination Product: irinotecan-eluting beads
Procedure: hepatic artery embolization

First Posted Date: 2011-01-27

Last Posted Date: 2021-12-20

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 4

Registration Number: NCT01285102

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer

Interventions: Drug: everolimus
Drug: carboplatin
Drug: pegylated liposomal doxorubicin hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2011-01-24

Last Posted Date: 2019-07-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 21

Registration Number: NCT01281514

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Home Terms & Conditions Privacy Policy